ArticleRheumatology (Oxford, England)2026
PROMIS displays strong construct validity in pediatric and adult patients with idiopathic inflammatory myopathies.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Update on clinimetric assessments in juvenile dermatomyositis: conceptual foundations, current tools, and future directions : (Narrative review describing the development, validation, and application of clinimetric outcome measures in juvenile dermatomyositis).Pediatric rheumatology online journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesWe assessed the validity of Patient-Reported Outcome Measurement Information System (PROMIS) for juvenile and adult-onset idiopathic inflammatory myopathies (JIIM/IIM) and determined associations with disease characteristics and assessments.
methodsPROMIS-49 or -57 questionnaires were completed by parents (n = 70) and pediatric (n = 49) or adult patients with IIM (n = 61). Construct validity was evaluated using legacy health-related quality of life (HRQoL) instruments and associations with disease assessments and clinical characteristics.
resultsAll groups reported decreased Physical Function (PF) (39.9-44.3, P < 0.001-0.002) compared with the reference population. All groups also reported significantly increased pain interference (49.6-55.8, P < 0.001), fatigue (49.5-55.1, P < 0.001-0.004) and anxiety (47.0-52.5, P < 0.001-0.043). PROMIS demonstrated excellent internal consistency (α > 0.9) and construct validity with legacy HRQoL instruments. Parents reported worse PF (39.7 vs 42.9, P < 0.001), more Fatigue (52.4 vs 48.5, P = 0.023) and higher Anxiety (49.6 vs 46.8, P = 0.032) than their children. PROMIS PF correlated best with disease activity measures (|r|=0.022-0.636), whereas Social Role, Anxiety and Depression correlated poorly with disease activity measures. Multiple PROMIS domains correlated with Patient and Parent Global Damage, but only parent PF correlated with Physician Global Damage (|r|=0.414). Several PROMIS domains had better correlations with disease assessments than the Medical Outcomes Study Short Form-36 (SF-36).
conclusionPROMIS offers a nuanced view of HRQoL that traditional disease assessments do not adequately capture. PROMIS has good construct validity and it may be more sensitive than legacy HRQoL measures. These findings support the incorporation of PROMIS into the assessment of IIM/JIIM to address comprehensive patient well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.